BRIEF-Citius Oncology Signs Exclusive Commercialization Agreement With EVERSANA To Support Planned Q4 2025 Launch Of LYMPHIR
Reuters
Oct 16
BRIEF-Citius Oncology Signs Exclusive Commercialization Agreement With EVERSANA To Support Planned Q4 2025 Launch Of LYMPHIR
Oct 16 (Reuters) - Citius Oncology Inc CTOR.O:
CITIUS ONCOLOGY SIGNS EXCLUSIVE COMMERCIALIZATION AGREEMENT WITH EVERSANA TO SUPPORT PLANNED Q4 2025 LAUNCH OF LYMPHIR™
CITIUS ONCOLOGY INC: CO PLANS TO COMMERCIALLY LAUNCH LYMPHIR IN UNITED STATES IN Q4 2025
Source text: ID:nPn9H30nNa
Further company coverage: CTOR.O
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.